The campaign aims to shift public perceptions of hospice care and encourage people to leave a gift in their will to support their local hospice.

The stock makes the NASDAQ top percentage gainer list, currently trading at 2.7402, up 1.3702, gaining 100.0146% on volume of ...

Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...

The Netflix documentary “The Remarkable Life of Ibelin” tells Mats’ story, nearly 10 years after he passed away from a serious muscle condition. He touched countless lives through the online ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

REGENXBIO (NASDAQ:RGNX – Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, ...

Enrique Antonio Campos, 22, passed away peacefully and suddenly on Wednesday, February 19, 2025. Enrique was born on ...